Regulatory
FDA clears first generics of AstraZeneca’s Farxiga, opening $8.5bn market to rivals
The US Food and Drug Administration has approved the first generic versions of Farxiga, marking a significant shift for one of AstraZeneca’s top-selling diabetes treatments.
